Meeting
2021 ASCO Annual Meeting
Identifying androgen receptor (AR) and genomic characteristics that define populations of patients with mHSPC who benefit from early PARP inhibition therapy with talazoparib.
Authors
Saro Kasparian
City of Hope, Duarte, CA
Saro Kasparian , Leanne Burnham , Rick Kittles , Zj Sun , Fornati Bedell , Justin Tran , Min Li , Tanya B. Dorff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Clinical Trial Registration Number
NCT04734730
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5097)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5097
Abstract #
TPS5097
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.
First Author: David Joseph Benjamin
Poster
2023 ASCO Genitourinary Cancers Symposium
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
First Author: Alice Bernard-Tessier
Poster
2021 Genitourinary Cancers Symposium
Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).
First Author: Fadi Taza
Poster
2020 Genitourinary Cancers Symposium
Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.
First Author: Alexandra Sokolova